{"id":40120,"date":"2021-03-12T07:21:38","date_gmt":"2021-03-12T07:21:38","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40120"},"modified":"2021-03-12T13:55:46","modified_gmt":"2021-03-12T13:55:46","slug":"no-benefit-from-brii-and-gsk-monoclonal-antibodies-in-activ-3-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40120","title":{"rendered":"No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

On 1 March 2021, two sub-studies of the ACTIV-3 trial using monoclonal antibodies (mAbs) to treat COVID-19 were closed to further enrolment, both due to futility. <\/strong><\/p>\n

This was based on planned early interim reviews and recommendations from the independent Data and Safety Monitoring Board (DSMB).<\/p>\n

Each review was based on approximately 340 participants and was designed to detect any signal of early benefit. [1]<\/p>\n

The investigational mAbs were VIR-7831 (developed by GSK and Vir Biotechnology) and a dual combination of BRII-196 and BRI-198 (developed by Brii Biosciences).<\/p>\n

The ACTIV-3 study is one of five studies looking to rapidly evaluate potential treatments for COVID-19, with each study able to look at multiple different treatments. [2]<\/p>\n

An earlier sub-study using bamlanivimab (LY-CoV555 from Eli Lilley) also closed early after finding no benefit in hospitalised participants. However, bamlanivimab has been shown to be effective (in the BLAZE-2 study) when used as prophylaxis against COVID-19. [3, 4]<\/p>\n

As with the BRII combination, LY-CoV555 continues to be studies in earlier infection as part of the six-arm ACTIV-2 study.<\/p>\n

A fourth study arm using AZD7442 (a mAb developed by AstraZeneca) is still ongoing and further compounds with also be added to ACTIV-3.<\/p>\n

References<\/div>\n
    \n
  1. NIH press release. NIH-sponsored ACTIV-3 clinical trial closes enrollment into two sub-studies. (4 March 2021).
    \nhttps:\/\/www.nih.gov\/news-events\/news-releases\/nih-sponsored-activ-3-clinical-trial-closes-enrollment-into-two-sub-studies<\/a><\/li>\n
  2. NIH. COVID-19 therapeutics prioritized for testing in clinical trials.
    \n    https:\/\/www.nih.gov\/research-training\/medical-research-initiatives\/activ\/covid-19-therapeutics-prioritized-testing-clinical-trials<\/a><\/li>\n
  3. Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early. HTB (22 January 2021).
    \n    https:\/\/i-base.info\/htb\/39663<\/a><\/li>\n
  4. Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study. HTB (24 February 2021).
    \n    https:\/\/i-base.info\/htb\/39886<\/a><\/li>\n<\/ol>\n

    This report was first posted on 5 March 2021.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base On 1 March 2021, two sub-studies of the ACTIV-3 trial using monoclonal antibodies (mAbs) to treat COVID-19 were closed to further enrolment, both due to futility. This was based on planned early interim reviews and recommendations …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-40120","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40120"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40120\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}